Table 3. Stratified analyses of Ezrin on overall survival in cancer patients among Asians and Caucasians.
| OS | No. of studies | Model | Pooled HR(95%) | Heterogeneity | |
|---|---|---|---|---|---|
| I2(%) | Pvalue | ||||
| Asian | 21 | Random | 2.21(1.72–2.83) | 74.80% | 0.000 |
| Digestive system cancer | 8 | Random | 1.83(1.17–2.88) | 87.0% | 0.000 |
| HNSCC | 3 | Fixed | 2.80(1.87–4.18) | 0% | 0.545 |
| Gynecologic cancer | 2 | Fixed | 2.73(1.78–4.18) | 0% | 0.453 |
| Osteosarcoma | 2 | Random | 7.21(0.65–80.17) | 81.0% | 0.022 |
| Hepatobiliary cancer | 3 | Fixed | 1.80(1.27–2.56) | 0% | 0.644 |
| NSCLC | 2 | Fixed | 1.97(1.23–3.18) | 0% | 0.747 |
| Other | 1 | — | 3.43(1.92–6.14) | — | — |
| Caucasian | 15 | Random | 1.41(0.95–2.09) | 81.30% | 0.000 |
| Digestive cancer | 2 | Random | 4.05(0.52–31.77) | 76.10% | 0.041 |
| HNSCC | 2 | Fixed | 2.38(1.13–5.02) | 39.00% | 0.200 |
| Gynecologic cancer | 3 | Random | 1.39(0.63–3.06) | 77.40% | 0.012 |
| Osteosarcoma | 2 | Fixed | 2.95(1.99–4.37) | 0% | 0.517 |
| Bladder cancer | 3 | Fixed | 0.46(0.27–0.78) | 0% | 0.967 |
| Other | 3 | Random | 1.04(0.28–3.90) | 92.20% | 0.000 |
Random-effects model was used when p-value for heterogeneity test < 0.05; otherwise, fixed-model was used.I2 the percentage of variability in HR attributable to heterogeneity. Abbreviations: HNSCC: squamous cell carcinoma of the head and neck; NSCLC: nonsmall cell lung cancer.